U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849921) titled 'Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors' on Feb. 23.
Brief Summary: This clinical trial aims to evaluate the efficacy and safety of CAR-T cell therapy in patients with relapsed/refractory hematologic malignancies.
Study Start Date: Nov. 07, 2024
Study Type: INTERVENTIONAL
Condition:
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
Hematologic Disease
Intervention:
DRUG: Cellular Therapy
This intervention involves the infusion of autologous or allogeneic CAR-T cells into patients with relapsed/refractory hematologic malignancies. CAR-T cells are modified to...